Drug intelligence / Profile preview

CUR203

Development stage: Preclinical
Lead developer: Curamys
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

CUR203 is an investigational cell therapy being developed by Curamys for the treatment of Alzheimer's Disease. The program utilizes Curamys's proprietary Cell-Fusion platform, which employs fusogenic stem cells designed to identify and fuse with damaged or unhealthy cells in the central nervous system. This fusion process is intended to facilitate the repair of dysfunctional cells or the delivery of therapeutic materials directly into the target cell's cytoplasm, potentially mitigating neurodegeneration. As of 2024, the program is in the discovery stage of development.

Beyond the preview

Go deeper on CUR203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CUR203.

Explore the full profile